NCT00299520

Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)

Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections.(ASSIST-1)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: —
• Sponsor: Arpida AG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, investigator-blind, comparative Phase 3 study. Patients will receive either iclaprim or linezolid for 10 to 14 days. Patients will be evaluated daily for the first four days of study treatment and then every other day, for up to 14 days of the treatment period, at End of Therapy, the Test Of Cure visit (7 to 14 days post treatment), and a Late Follow-up (F/U) visit (7 to 14 days after the TOC visit).

Detailed description

Primary Objective: The primary objective of this study is to compare the clinical cure rates of iclaprim and linezolid at the test of cure (TOC) visit (7 to 14 days after the end of treatment). Secondary Objectives: The secondary objectives of this study are to compare iclaprim with linezolid regarding: * Clinical efficacy at the end of study medication treatment; * Time to resolution of systemic and local signs and symptoms of complicated skin and skin structure infection (cSSSI); * Clinical outcome in the microbiologically evaluable (ME) population; * Bacteriologic outcome in the ME population; * Bacteriologic eradication rates of Baseline (BL) pathogens; * Clinical outcome in the modified intent-to-treat (MITT) population; * Bacteriologic outcome in the MITT population; * Baseline in vitro susceptibility of isolated pathogens in the ME population; and * Safety and tolerability of iclaprim treatment.

Conditions

• Complicated Skin and Skin Structure Infection

Interventions

Type	Name	Description
DRUG	intravenous iclaprim or intravenous linezolid

Timeline

• Start date: 2005-06-01
• Completion: 2006-07-01
• First posted: 2006-03-07
• Last updated: 2008-04-04

Locations

5 sites across 1 country: United States